Company profile

Ticker
A
Exchange
Website
CEO
Michael R. McMullen
Employees
Incorporated in
Location
Fiscal year end
Former names
Agilent Technologies Inc
SEC CIK
IRS number
770518772

A stock data

(
)

Calendar

19 Dec 19
28 Jan 20
31 Oct 20

News

Company financial data Financial data

Quarter (USD) Oct 19 Jul 19 Apr 19 Jan 19
Revenue 1.37B 1.27B 1.24B 1.28B
Net income 191M 182M 504M
Diluted EPS 0.63 0.6 0.57 1.57
Net profit margin 14.99% 14.70% 39.25%
Operating income 250M 225M 216M 250M
Net change in cash -383M -390M 98M -190M
Cash on hand 1.38B 1.77B 2.16B 2.06B
Cost of revenue 630M 582M 569M 577M
Annual (USD) Oct 19 Oct 18 Oct 17 Oct 16
Revenue 5.16B 4.91B 4.47B 4.2B
Diluted EPS 3.37 0.97 2.1 1.4
Operating income 941M 904M 807M 615M
Net change in cash -865M -431M 389M 286M
Cash on hand 1.38B 2.25B 2.68B 2.29B
Cost of revenue 2.36B 2.23B 2.06B 2.01B

Financial data from Agilent earnings reports

84.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 674 670 +0.6%
Opened positions 74 78 -5.1%
Closed positions 70 110 -36.4%
Increased positions 226 229 -1.3%
Reduced positions 241 238 +1.3%
13F shares
Current Prev Q Change
Total value 20.05B 19.67B +1.9%
Total shares 261.41M 264.02M -1.0%
Total puts 2.25M 1.31M +72.0%
Total calls 1.16M 1.42M -18.2%
Total put/call ratio 1.9 0.9 +110.2%
Largest owners
Shares Value Change
BLK BlackRock 25.2M $1.93B +0.2%
Vanguard 25.1M $1.92B +0.6%
N Price T Rowe Associates 22.99M $1.76B -7.2%
STT State Street 13.39M $1.03B -1.5%
Wellington Management 8.33M $638.54M -4.4%
State Farm Mutual Automobile Insurance 5.49M $420.65M 0.0%
Artisan Partners Limited Partnership 5.31M $407.22M +1.2%
Geode Capital Management 5.17M $395.83M +5.8%
NMR Nomura 5.06M $378.98M +1103.8%
D. E. Shaw & Co. 5.04M $386.36M +2.7%
Largest transactions
Shares Bought/sold Change
NMR Nomura 5.06M +4.64M +1103.8%
IVZ Invesco 4.77M -4.46M -48.3%
Harris Associates L P 2.92M +2.92M NEW
Pershing Square Capital Management 2.92M +2.92M NEW
Winslow Capital Management 10.76K -2.72M -99.6%
GS Goldman Sachs 4.78M +1.84M +62.8%
N Price T Rowe Associates 22.99M -1.79M -7.2%
American Century Companies 2.5M -1.59M -38.8%
Epoch Investment Partners 2.15M +1.5M +232.2%
WFC Wells Fargo & Company 1.02M -1.47M -59.2%

Financial report summary

?
Risks
  • Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated.
  • If we do not introduce successful new products and services in a timely manner to address increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards, our products and services may become obsolete, and our operating results may suffer.
  • General economic conditions may adversely affect our operating results and financial condition.
  • Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income.
  • Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies.
  • Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.
  • Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business and we may not realize the operational or financial benefits from such actions.
  • Our business will suffer if we are not able to retain and hire key personnel.
  • Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected.
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.
  • Our customers and we are subject to various governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
  • We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.
  • Some of our products are subject to particularly complex regulations such as regulations of toxic substances and failure to comply with such regulations could harm our business.
  • Our business may suffer if we fail to comply with government contracting laws and regulations.
  • Our retirement and post retirement pension plans are subject to financial market risks that could adversely affect our future results of operations and cash flows.
  • The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business.
  • If we are unable to successfully manage the consolidation and streamlining of our manufacturing operations, we may not achieve desired efficiencies and our ability to deliver products to our customers could be disrupted.
  • Our operating results may suffer if our manufacturing capacity does not match the demand for our products.
  • Dependence on contract manufacturing and outsourcing other portions of our supply chain, including logistics and third-party package delivery services, may adversely affect our ability to bring products to market and damage our reputation. Dependence on outsourced information technology and other administrative functions may impair our ability to operate effectively.
  • Environmental contamination from past and ongoing operations could subject us to substantial liabilities.
  • Third parties may claim that we are infringing their intellectual property and we could suffer significant litigation or licensing expenses or be prevented from selling products or services.
  • Third parties may infringe our intellectual property and we may suffer competitive injury or expend significant resources enforcing our rights.
  • Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on our results of operations, financial condition and liquidity.
  • If tax incentives change or cease to be in effect, our income taxes could increase significantly.
  • We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations.
  • If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations could be seriously harmed.
  • If we experience a significant disruption in, or breach in security of, our information technology systems, or if we fail to implement new systems and software successfully, our business could be adversely affected.
  • Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity.
  • Regulations related to “conflict minerals” may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.
  • We cannot assure that we will continue to pay dividends on our common stock.
  • Overview and Executive Summary
  • Critical Accounting Policies and Estimates
  • Adoption of New Pronouncements
  • Other income (expense), net
  • 2017 U.S. Tax Reform - Tax Cuts and Jobs Act
  • Life Sciences and Applied Markets
  • Gross Margin and Operating Margin
  • Gross Margin and Operating Margin
  • Gross Margin and Operating Margin
  • Liquidity and Capital Resources
  • Definition and Limitations of Internal Control over Financial Reporting
  • 1. OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
  • 2. NEW ACCOUNTING PRONOUNCEMENTS
  • Recently Adopted Accounting Pronouncements
  • New Accounting Pronouncements Not Yet Adopted
  • Transaction Price Allocated to the Remaining Performance Obligations
  • 5. SHARE-BASED COMPENSATION
  • Description of Share-Based Plans
  • Impact of Share-based Compensation Awards
  • 2017 U.S. Tax Reform - Tax Cuts and Jobs Act
  • 7. NET INCOME PER SHARE
  • 9. PROPERTY, PLANT AND EQUIPMENT, NET
  • 10. GOODWILL AND OTHER INTANGIBLE ASSETS
  • 12. FAIR VALUE MEASUREMENTS
  • Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
  • Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
  • 14. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
  • Indemnifications to Officers and Directors
  • 16. COMMITMENTS AND CONTINGENCIES
  • 19. STOCKHOLDERS' EQUITY
  • 20. SEGMENT INFORMATION
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: alter, AOCI, artificial, assigned, attrition, biopharma, BioTek, climate, commensurate, constituted, deep, default, diet, disaggregated, discretionary, distinct, documented, extinguishment, extreme, Frederick, frequency, guarantee, history, incident, insignificant, IVDR, learning, lending, lessor, leverage, leveraging, Lionheart, machine, marketplace, matter, merger, microplate, modestly, possession, proforma, RDFV, reader, redeemed, relief, resilience, resort, ROU, royalty, scoring, skill, smart, spare, standby, storage, stricter, subtotal, surveillance, swiftly, tie, tradename, unaudited, unbilled, undertook, unhealthy, Union, Unspecified, Vermont, version, weather
Removed: achievement, aforementioned, assisted, assured, biotech, biotechnology, collectability, collection, competitor, compute, condensed, consolidating, consultation, correct, count, cut, deliverable, distributed, diversity, ESP, essential, establishment, fee, forma, geography, grew, improvement, incorrect, indenture, inflow, instability, installed, interchangeable, landscape, launched, mentioned, microarray, modest, Notwithstanding, outflow, penetration, persuasive, physiology, player, predominantly, preparing, pro, reflecting, retrospectively, revised, revision, revolving, satisfied, scanning, Seahorse, sequenced, shift, showed, similarly, situated, TPE, transact, twenty, uncollectible, undelivered, violated, VSOE, wrote